Vernon T. Phan
YOU?
Author Swipe
View article: Supplementary Table and Supplementary Figures 1-2 from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance
Supplementary Table and Supplementary Figures 1-2 from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance Open
Supplementary Table S1. Percentage of enzyme activity following dialysis compared to a non-compound treated control; Supplementary Figure S1. PRN1371 inhibited SNU16 cell proliferation as assessed by BrdU incorporation; Supplementary Figur…
View article: Data from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Data from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
Androgen receptor (AR) is expressed in 90% of estrogen receptor alpha–positive (ER+) breast tumors, but its role in tumor growth and progression remains controversial. Use of two anti-androgens that inhibit AR nuclear localizati…
View article: Supplementary Table and Supplementary Figures 1-2 from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance
Supplementary Table and Supplementary Figures 1-2 from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance Open
Supplementary Table S1. Percentage of enzyme activity following dialysis compared to a non-compound treated control; Supplementary Figure S1. PRN1371 inhibited SNU16 cell proliferation as assessed by BrdU incorporation; Supplementary Figur…
View article: Supplementary Figure Legends from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Supplementary Figure Legends from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
Supplementary Figure Legends
View article: Data from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance
Data from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance Open
An increasing number of cancers are known to harbor mutations, translocations, or amplifications in the fibroblast growth factor receptor (FGFR) family of kinases. The FGFR inhibitors evaluated in clinical trials to date have shown promise…
View article: Supplementary Tables 1-3 from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Supplementary Tables 1-3 from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
S1. E2 induces AR binding at sites that overlap with ER binding. S2. Enza alters expression of E2-regulated genes in PT12 xenograft tumors. S3. Pathway analysis of Enza-regulated genes in PT12 xenograft tumors.
View article: Supplementary Figures 1-6 from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Supplementary Figures 1-6 from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
S1. Enza or AR knockdown decrease baseline and E2-induced proliferation of breast cancer cells in vitro. S2. E2 induces and Enza inhibits AR nuclear localization. S3. AR and ER binding in MCF7 cells. S4. Enza synergizes with anti-estrogens…
View article: Supplementary Methods from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Supplementary Methods from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
Supplementary Methods
View article: Supplementary Tables 1-3 from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Supplementary Tables 1-3 from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
S1. E2 induces AR binding at sites that overlap with ER binding. S2. Enza alters expression of E2-regulated genes in PT12 xenograft tumors. S3. Pathway analysis of Enza-regulated genes in PT12 xenograft tumors.
View article: Data from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance
Data from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance Open
An increasing number of cancers are known to harbor mutations, translocations, or amplifications in the fibroblast growth factor receptor (FGFR) family of kinases. The FGFR inhibitors evaluated in clinical trials to date have shown promise…
View article: Supplementary Methods from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Supplementary Methods from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
Supplementary Methods
View article: Supplementary Figure Legends from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Supplementary Figure Legends from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
Supplementary Figure Legends
View article: Supplementary Figures 1-6 from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Supplementary Figures 1-6 from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
S1. Enza or AR knockdown decrease baseline and E2-induced proliferation of breast cancer cells in vitro. S2. E2 induces and Enza inhibits AR nuclear localization. S3. AR and ER binding in MCF7 cells. S4. Enza synergizes with anti-estrogens…
View article: Data from Cooperative Dynamics of AR and ER Activity in Breast Cancer
Data from Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
Androgen receptor (AR) is expressed in 90% of estrogen receptor alpha–positive (ER+) breast tumors, but its role in tumor growth and progression remains controversial. Use of two anti-androgens that inhibit AR nuclear localizati…
View article: Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the Treatment of Solid Tumors
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the Treatment of Solid Tumors Open
Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric…
View article: Cooperative Dynamics of AR and ER Activity in Breast Cancer
Cooperative Dynamics of AR and ER Activity in Breast Cancer Open
Androgen receptor (AR) is expressed in 90% of estrogen receptor alpha–positive (ER+) breast tumors, but its role in tumor growth and progression remains controversial. Use of two anti-androgens that inhibit AR nuclear localization, enzalut…
View article: Prolonged and tunable residence time using reversible covalent kinase inhibitors
Prolonged and tunable residence time using reversible covalent kinase inhibitors Open